There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Ovarian cancer is the most leading cause of death and the third most common gynecologic
malignancy in women. Traditional chemotherapy has inevitable drawbacks of nonspecific
tumor targeting, high toxicity, and poor therapeutic efficiency. In order to overcome
such shortcomings, we prepared a novel nano-carrier drug-delivery system to enhance
the anti-tumor efficiency.
Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic.
Cancer therapies that exploit targeting ligands to deliver attached cytotoxic drugs selectively to malignant cells are currently receiving significant attention. While antibody-targeted drugs have been the first to enter the clinic, recent studies demonstrate that the vitamin folic acid can also be used to deliver attached imaging and therapeutic agents selectively to malignant cells in both animal tumor models and human cancer patients. Thus, folate conjugates bind to folate receptors that are overexpressed on approximately 40% of human cancers and mediate internalization of their attached drugs by receptor-mediated endocytosis. With the use of proper linkers, folate-targeted drugs can be released inside their target cells where they can perform their desired cytotoxic functions. Based on this strategy, six folate-targeted drugs are currently in human clinical trials.
Journal ID (iso-abbrev): J. Exp. Clin. Cancer Res.
Title:
Journal of experimental & clinical cancer research : CR
Publisher:
Springer Nature America, Inc
ISSN
(Electronic):
1756-9966
ISSN
(Print):
0392-9078
Publication date
(Electronic):
Feb 26 2018
Volume: 37
Issue: 1
Affiliations
[1
]
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua
Xi Road, Jinan, Shandong, 250012, People's Republic of China.
[3
]
Department of Biomedical Engineering, School of Control Science and Engineering, Shandong
University, Jinan, Shandong, 250012, China.
[4
]
Department of Chemistry and Chemical Engineering, Shandong University, Jinan, Shandong,
250012, China.
[5
]
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua
Xi Road, Jinan, Shandong, 250012, People's Republic of China. songkun2001226@sdu.edu.cn.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.